Cited by 221Lipid metabolism and disordersLipoproteins and Cardiovascular HealthLipid metabolism and biosynthesis

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Angiopoietin-like 3 in lipoprotein metabolism

Open access

Kersten, Sander·2017·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2017.119

Open this paper in CoChat — free account

Abstract

Triglycerides and cholesterol circulate in the bloodstream as part of various lipoprotein particles. Three members of the angiopoietin-like (ANGPTL) protein family - ANGPTL3, ANGPTL4 and ANGPTL8 - have emerged as important regulators of plasma lipoprotein levels by inhibiting the enzyme lipoprotein lipase. Here, I review the role of ANGPTL3 in lipoprotein metabolism. In contrast to ANGPTL4 and ANGPTL8, ANGPTL3 is exclusively produced in the liver and can therefore be classified as a true hepatokine. ANGPTL3 cooperates with ANGPTL8 to inhibit lipoprotein lipase and is mostly active after feeding, whereas ANGPTL4 is mostly active after fasting. Inactivation of ANGPTL3 in mice reduces plasma triglyceride and free fatty acid levels and suppresses atherosclerosis. In humans, homozygous loss-of-function mutations in ANGPTL3 lead to low plasma levels of low-density lipoproteins, high-density lipoproteins and triglycerides, a condition referred to as familial combined hypolipidaemia. Heterozygous carriers of loss-of-function mutations in ANGPTL3 have a lower risk of coronary artery disease than non-carriers. At present, researchers are investigating antisense oligonucleotide and monoclonal antibody-based inactivation of ANGPTL3 in human clinical trials for the therapeutic management of dyslipidaemia and atherosclerosis. Thus, ANGPTL3 is an important liver-derived regulator of lipoprotein metabolism that holds considerable promise as a target for atherosclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2017.119

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2 retracted

RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Yi, P., Park, J.-S., & Melton, D. A. (2013) · Cell · doi:10.1016/j.cell.2013.04.008 · Cited by 449
Retracted
Retraction Notice to: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Peng, Y., Park, J.-S., & Melton, D. A. (2016) · Cell · doi:10.1016/j.cell.2016.12.017 · Cited by 49
Retracted
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 573
Self-citation
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Self-citation

Show all 80 references

Sorted by citations

The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 416
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Evinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279
Causes and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239
Lipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225
Self-citation
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
Carbone, C., Piro, G., Merz, V., Simionato, F., Santoro, R., Zecchetto, C., Tortora, G., & Melisi, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020431 · Cited by 200
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404147 · Cited by 213
ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue
Iizuka, K., Takao, K., & Yabe, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587189 · Cited by 158
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Mouse models of atherosclerosis in translational research
Ilyas, I., Little, P. J., Liu, Z., Xu, Y., Kamato, D., Berk, B. C., Weng, J., & Xu, S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.009 · Cited by 122
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89
Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease
Cadby, G., Giles, C., Melton, P. E., Huynh, K., Mellett, N. A., Duong, T., Nguyen, T. A., Cinel, M. A., Smith, A., Olshansky, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30875-7 · Cited by 108
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 116
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02494-2 · Cited by 105
The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation
Abu‐Farha, M., Ghosh, A., Al‐Khairi, I., Madiraju, S. R. M., Abubaker, J. A., & Prentki, M. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101067 · Cited by 93
Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Chen, P., Gao, W.-Y., Liou, J.-W., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147310 · Cited by 80
Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism
Kristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Meiyappan, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920202117 · Cited by 72
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 68
Dietary Flavonoids as Modulators of Lipid Metabolism in Poultry
Tan, Z., Halter, B., Liu, D., Gilbert, E. R., & Cline, M. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.863860 · Cited by 67
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 66
A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin
Tolonen, J.-P., Heikkilä, M., Malinen, M., Lee, H.-M., Palvimo, J. J., Wei, G.-H., & Myllyharju, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03387-9 · Cited by 63
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 63
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 60
Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver–Adipose Tissue Crosstalk
Morán-Costoya, A., Proenza, A. M., Gianotti, M., Lladó, I., & Valle, A. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0044 · Cited by 58
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.008 · Cited by 58
Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
Biterova, E., Esmaeeli, M., Alanen, H. I., Saaranen, M., & Ruddock, L. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-25237-7 · Cited by 53
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Self-citation
Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial
Wang, J., Zhao, J. Z., Yan, C., Xi, C., Wu, C., Zhao, J., Li, F., Ding, Y., Zhang, R., Qi, S., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.03.006 · Cited by 52
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01071-1 · Cited by 48
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
Kim, T. H., Hong, D.-G., & Yang, Y. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121903 · Cited by 56
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 49
New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases
Su, X., & Peng, D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0659-y · Cited by 45
Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome
Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 47
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 44
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 45
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 43
Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Tikkanen, E., Minicocci, I., Hällfors, J., Costanzo, A. D., D’Erasmo, L., Poggiogalle, E., Donini, L. M., Würtz, P., Jauhiainen, M., Olkkonen, V. M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312021 · Cited by 41
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency
Arca, M., D’Erasmo, L., & Minicocci, I. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000668 · Cited by 43
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 41
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity
Barchetta, I., Cimini, F. A., Chiappetta, C., Bertoccini, L., Ceccarelli, V., Capoccia, D., Gaggini, M., Cristofano, C. D., Rocca, C. D., Silecchia, G., et al. (2020) · Liver International · doi:10.1111/liv.14554 · Cited by 37
Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes
Latorre, J., Ortega, F. J., Liñares‐Pose, L., Moreno‐Navarrete, J. M., Lluch, A., Comas, F., Oliveras‐Cañellas, N., Ricart, W., Höring, M., Zhou, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102697 · Cited by 35
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 35
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Emerging roles of angiopoietin‐like proteins in inflammation: Mechanisms and potential as pharmacological targets
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 33
GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 33
Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 35
Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 38
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 39
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
Foss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 31
Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
Stefanutti, C., Chan, D. C., Giacomo, S. D., Morozzi, C., & Watts, G. F. (2022) · Pharmaceuticals · doi:10.3390/ph15111389 · Cited by 30
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
Yang, L., Yin, R., Wang, Z., Wang, X., Zhang, Y., & Zhao, D. (2019) · BioMed Research International · doi:10.1155/2019/3814687 · Cited by 27
Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits
Tierney, E., Remaley, A. T., Thurm, A., Jager, L. R., Wassif, C. A., Kratz, L. E., Bailey-Wilson, J. E., Bukelis, I., Sarphare, G., Jung, E. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01580-8 · Cited by 26
Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the “Prime Time” of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?
Yang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice
Zhao, Z., Deng, X., Jia, J., Zhao, L., Wang, C., Cai, Z., Guo, C. Y., Yang, L., Wang, D., Ma, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154921 · Cited by 26
Angiopoietin-like proteins in atherosclerosis
Liu, Y., Zhang, C., Jiang, J.-F., Cheng, Z.-B., Zhou, Z., Tang, M.-Y., Sun, J.-X., & Huang, L. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.024 · Cited by 25
Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
Sun, T., Zhan, W., Wei, L., Xu, Z., Li, F., Yang, Z., Wang, C., & Zhang, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01580-z · Cited by 25
Food-Borne Exposure of Juvenile Rainbow Trout (Oncorhynchus mykiss) to Benzotriazole Ultraviolet Stabilizers Alone and in Mixture Induces Specific Transcriptional Changes
Giraudo, M., Colson, T. L., Silva, A. O. D., Lu, Z., Gagnon, P., Brown, L. L., & Houde, M. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4676 · Cited by 25
The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells
Chen, P., Chao, T.-Y., Hsu, H., Wang, C., Lin, C.-Y., Gao, W.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189853 · Cited by 25
Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice
Xiao, H., Liang, L., Luo, Z.-F., & Sun, Z. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.006 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 23
A hepatokine derived from the ER protein CREBH promotes triglyceride metabolism by stimulating lipoprotein lipase activity
Kim, H., Song, Z., Zhang, R., Davies, B. S. J., & Zhang, K. (2023) · Science Signaling · doi:10.1126/scisignal.add6702 · Cited by 22
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
The interplay between the muscle and liver in the regulation of glucolipid metabolism
Cheng, C., Xie, L., Zhang, M., Shama, S., Cheng, K. K. Y., & Jia, W. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad073 · Cited by 23
Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Mihăilă, R. G. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x15666190522100041 · Cited by 25
Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8
Oldoni, F., Bass, K., Kozlitina, J., Hudson, H., Shihanian, L. M., Gusarova, V., Cohen, J. C., & Hobbs, H. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab120 · Cited by 20
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190621120523 · Cited by 22
Role of GALNT2 on Insulin Sensitivity, Lipid Metabolism and Fat Homeostasis
Antonucci, A., Marucci, A., Trischitta, V., & Paola, R. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020929 · Cited by 22
Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats
Dong, Q., Kuefner, M., Deng, X., Bridges, D., Park, E. A., Elam, M. B., & Raghow, R. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0202-x · Cited by 20
Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi
Butler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 21
Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins
DeForest, N., Kavitha, B., Hu, S., Isaac, R., Krohn, L., Wang, M., Du, X., De Arruda Saldanha, C., Gylys, J., Merli, E., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100339 · Cited by 21
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 22
The endocrine role of hepatokines: implications for human health and disease
Iglesias, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663353 · Cited by 23
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 19
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
Unexpected omega-3 activities in intracellular lipolysis and macrophage foaming revealed by fluorescence lifetime imaging
Tang, H., Liu, Z., Han, G., Geng, J., Liu, B., Zhang, R., & Zhang, Z. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321255121 · Cited by 19
Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
Wang, J., Zheng, W., Zheng, S., Yuan, Y., Wen, W., Cui, W., Xue, L., Sun, X., Shang, H., Zhang, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.023 · Cited by 18
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
Chan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 19
Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia
Cruz‐Bautista, I., Huerta‐Chagoya, A., Moreno-Macías, H., Rodríguez-Guillén, R., Ordóñez-Sánchez, M. L., Segura-Kato, Y., Mehta, R., Almeda‐Valdés, P., Gómez-Munguía, L., Chávez, X. R.-D., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01436-6 · Cited by 20
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18
ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
Zhong, F., Liu, S., Li, Y., Li, G., Liu, M., Wang, J., Cui, W., Suo, Y., & Gao, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01632-y · Cited by 18
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen, R. F., Hovingh, G. K., & Stroes, E. S. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000898 · Cited by 18
Evaluation of rs1748195 ANGPTL3 gene polymorphism in patients with angiographic coronary artery disease compared to healthy individuals
Afkhami, N., Aghasizadeh, M., Hafezi, S. G., Zare‐Feyzabadi, R., Soflaei, S. S., Rashidmayvan, M., Rastegarmoghadam-Ebrahimian, A., Khanizadeh, K., Safari, N., Ferns, G. A., et al. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2105 · Cited by 14
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 15
The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models
Lin, C.-Y., Chen, P., Hsu, H., Gao, W.-Y., Wu, M., & Yen, J.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012485 · Cited by 14
Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis
Ji, B., Liu, J., Yin, Y., Xu, H. M., Shen, Q., & Yu, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06124-0 · Cited by 14
Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
ANGPTL3 negatively regulates IL-1β-induced NF-κB activation by inhibiting the IL1R1-associated signaling complex assembly
Zhang, Y., Zhang, Z.-T., Wan, S.-Y., Yang, J. X., Wei, Y., Chen, H., Zhou, W.-Z., Song, Q., Niu, S., Zheng, L., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad053 · Cited by 13
Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction
Schinzari, F., Vizioli, G., Campia, U., Tesauro, M., & Cardillo, C. (2021) · Biomedicines · doi:10.3390/biomedicines9081037 · Cited by 13

Authors: Kersten, S.
Affiliations: Wageningen University & Research (NL)
Corresponding author: Kersten, Sander
ORCID: Kersten, Sander
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-06
Volume: 13
Issue: 12
Pages: 731-739
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2017.119
OpenAlex: W2761312904
Semantic Scholar: de449b0f2ed915d896023302b106994d388fefb6
Cited by: 220
References: 80
Citations by year: 2026: 23 · 2025: 30 · 2024: 20 · 2023: 22 · 2022: 27 · 2021: 47 · 2020: 25 · 2019: 13 · 2018: 12 · 2017: 1
FWCI: 1.98
Type: journal article
Language: en
Open access: green
research.wur.nl
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Socio-Environmental Systems Modeling (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Fondation Leducq
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords: ANGPTL3, angiopoietin-like proteins, lipoprotein lipase inhibition, lipoprotein metabolism, hepatokines, atherosclerosis, loss-of-function mutations, coronary artery disease, dyslipidemia, antisense oligonucleotides, monoclonal antibodies, triglycerides, free fatty acids, ANGPTL4, ANGPTL8
MeSH terms: Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Animals, Antibodies, Monoclonal, Fasting, Fatty Acids, Nonesterified, Food, Humans, Lipoprotein Lipase, Lipoproteins, Liver, Mutation, Triglycerides, Oligonucleotides, Antisense, Dyslipidemias, Atherosclerosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiopoietin-like 3 in lipoprotein metabolism

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks